Market Cap | 7.91M | P/E | - | EPS this Y | 4.60% | Ern Qtrly Grth | - |
Income | -38.47M | Forward P/E | -0.23 | EPS next Y | 14.20% | 50D Avg Chg | 5.00% |
Sales | 1.73M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -54.00% |
Dividend | N/A | Price/Book | 0.90 | EPS next 5Y | - | 52W High Chg | -91.00% |
Recommedations | 2.70 | Quick Ratio | 1.99 | Shares Outstanding | 14.82M | 52W Low Chg | 50.00% |
Insider Own | 29.74% | ROA | -78.21% | Shares Float | 6.90M | Beta | 1.94 |
Inst Own | 37.57% | ROE | -161.85% | Shares Shorted/Prior | 74.01K/188.47K | Price | 0.53 |
Gross Margin | 5.19% | Profit Margin | - | Avg. Volume | 50,630 | Target Price | 11.67 |
Oper. Margin | -2,166.30% | Earnings Date | Mar 27 | Volume | 137,793 | Change | 0.00% |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Oppenheimer | Perform | Oct 31, 22 |
Roth Capital | Sell | Oct 20, 22 |
Noble Capital Markets | Market Perform | Sep 20, 22 |
HC Wainwright & Co. | Buy | Aug 16, 22 |
Oppenheimer | Outperform | Mar 30, 22 |
Raymond James | Outperform | Mar 30, 22 |
Maxim Group | Buy | Dec 20, 21 |
HC Wainwright & Co. | Buy | Dec 20, 21 |
Jefferies | Buy | Nov 30, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Gordon Gary B. | Chief Medical Office.. Chief Medical Officer | Feb 26 | Option | 5.16 | 3,000 | 15,480 | 11,520 | 02/26/21 |
Gordon Gary B. | Chief Medical Office.. Chief Medical Officer | Feb 26 | Sell | 17.46 | 3,000 | 52,380 | 8,520 | 02/26/21 |
Mamluk Roni | President & CEO President & CEO | Feb 24 | Sell | 18.38 | 33,126 | 608,856 | 145,345 | 02/24/21 |